Pulse nav.journalClub Debates activos Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes | Synapse

September 23, 2020Open Access

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp VERTIS CV ClinicalTrials.gov number, NCT01986881.).

Leer artículo completoexternamente

Me gusta

Guardar

Compartir

Ver artículo completo

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Cannon et al. (Wed,) studied this question.

synapsesocial.com/papers/69d7f43ea2a48916bbbee7ea https://doi.org/https://doi.org/10.1056/nejmoa2004967

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multiple Testing in Group Sequential Trials Using Graphical Approaches2013 · 120 citations
2Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes2017 · 1,393 citations
3Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease2015 · 728 citations
4Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,000 citations
5KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update2012 · 1,346 citations